反应详情

The title compound (30 mg, 15%) was prepared as an off-white solid from (4-{[(2-hydroxyethyl)amino]sulfonyl}phenyl)boronic acid (98 mg, 0.4 mmol), 2-bromo-5-[({1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl}methyl)oxy]pyridine (153 mg, 0.4 mmol), Pd(PPh3)4 (100 mg, 0.14 mmol), 2M Na2CO3 (2 mL) and DME (4 mL) in a manner similar to Example 21, Step 3. 1H NMR (400 MHz, CDCl3): δ 8.39 (s, 1H), 8.07 (d, 2H, J=8.2 Hz), 7.93 (d, 2H, J=8.2 Hz), 7.72 (d, 1H, J=8.6 Hz), 7.30 (d, 1H, J=6.5 Hz), 5.07 (t, 1H, J=5.8 Hz), 4.28-4.18 (m, 2H), 3.94 (d, 2H, J=6.0 Hz), 3.73-3.65 (m, 2H), 3.17-3.04 (m, 4H), 2.96-2.80 (m, 1H), 2.06-1.92 (m, 3H), 1.57-1.40 (m, 2H), 1.28 (d, 6H, J=6.9 Hz); LRMS (ESI), m/z 502 (M+H).